Going forward, alternative ways of targeting VEGF, such as the use of the beta-blocker, propranolol [82] and the targeting of other pathological pathways that lead to ROP, such as LCPUFAs and IGF-1 may warrant further investigation. Here, IGF1 is linked to retinopathy of prematurity.